We’re a company focused on tackling some of the toughest health challenges. Our success is reflected in our management team, which is individually and collectively focused on improving the lives of individuals who are faced with debilitating diseases. Our management team are leaders in their respective fields, including research, development and commercialization, to name a few.
Executive Leadership for Glenmark Pharmaceuticals, US
President, North America and Global API
Robert Matsuk is President of North America at Glenmark Pharmaceuticals. He is responsible for the company’s overall generics and branded pharmaceutical business across North America, as well as the Global API Business at Glenmark.
Prior to joining Glenmark in 2014, he was Executive Vice President and Chief Strategy Officer at HighPoint Solutions, where he had overall responsibility for the Life Sciences business. He also held senior leadership positions within the Life Sciences industry at PricewaterhouseCoopers and Computer Sciences Corporation.
He received his Master in Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University and graduated from the Philadelphia College of Pharmacy and Science with a Bachelor of Pharmacy degree.
Executive Vice President & Head, US Generics Business
Sanjeev Krishan is EVP & Head, US Generics Business, at Glenmark Pharmaceuticals, responsible for all commercial operations of its Generics Business in the US. He has worked at Glenmark since 2005 and has more than 21 years of experience across the generic pharmaceutical value chain.
Prior to Glenmark, he worked for Dr. Reddy’s Laboratories for nearly eight years in a variety of roles. His responsibilities included management of APIs and generic fixed dose formulations for various parts of the world.
He is a graduate with a degree in Chemistry from Delhi University, and received a Master of Science in Biotechnology from the Indian Institute of Technology. He also completed his MBA in marketing and finance at Symbiosis Institute.
Executive Leadership for Innovation Company
Alessandro Riva, M.D.
Chief Executive Officer
Alessandro Riva, M.D. joined Glenmark’s new Innovation Company in April, 2019 to lead the company as Chief Executive Officer.
Most recently, Alessandro was Executive Vice President, Global Head of Hematology and Oncology Therapeutics for Gilead Sciences. In addition, he was appointed head of the Gilead’s Cell Therapy organization, a role that included oversight of Kite Pharma and Cell Design Labs. Prior to joining Gilead, he was Global Head of Oncology Development at Novartis Pharmaceuticals from 2005 to 2016 where he was responsible for the global development and registration of more than 30 oncology compounds, including targeted and immuno-oncology therapies. Alessandro was President at Interim of the Oncology Business Unit at Novartis from January 2016 to June 2016.
An Oncologist/Hematologist by training, Alessandro received his bachelor’s degree in medicine from the Università degli Studi di Milano in 1986 and a Certificate Board in Oncology/Hematology from the same institution in 1989. He began his career at Famitalia Carlo Erba, where he developed and registered epidoxorubicin in various solid tumors and idarubicin in acute myeloid leukemia. He later moved to clinical development leadership positions within Rhône-Poulenc Rohrer and Aventis.
Alessandro co-founded the Breast Cancer International Research Group (BIRG), a global nonprofit cooperative group, and Cancer International Research Group (CIRG), a global clinical research organization, for which he served as Chief Executive Officer and Chief Medical Officer. He has authored or co-authored more than 100 papers and abstracts in the field of Oncology.
Alessandro is a member of the American Society of Clinical Oncology and the European Society for Medical Oncology.
Mahboob Rahman, M.D.
President & Chief Medical Officer
Dr. Mahboob Rahman is the President & Chief Medical Officer at Glenmark Pharmaceuticals and oversees Global Clinical Sciences, Portfolio and Program Management, Global Clinical & Pharmacovigilance Quality Assurance, Regulatory Affairs and Drug Metabolism and Pharmacokinetics.
He has more than 30 years of clinical practice and research experience, as well as teaching experience at three medical schools (Harvard, University of Pennsylvania, and Rutgers/Robert Wood Johnson). He has authored more than a hundred scientific papers and book chapters. Dr. Rahman most recently served as Vice President & Therapeutic Area Head for Immunology in Global Clinical Development at Novartis. Prior to Novartis, he has worked with Centocor/Johnson & Johnson and Pfizer.
During his tenure at these three companies, he was involved in the approval of a number indications for multiple compounds. Dr. Rahman holds a Medical Degree from Dhaka Medical College, and a Ph.D. in Molecular Biology from the Medical College of Pennsylvania. He completed his Internal Medicine Residency at the Medical College of Pennsylvania, and Rheumatology Fellowship training at Massachusetts General Hospital/Harvard Medical School. He then served as an Instructor in Medicine at Harvard Medical School.
At the University of Pennsylvania, he served as an Adjunct Professor of Medicine for Rheumatology. Dr. Rahman is a US Board Certified Rheumatologist and continues to be a practicing physician at Rutgers/Robert Wood Johnson School of Medicine, where he is also a Clinical Professor of Medicine for Rheumatology.
Our global executive leadership comprises the company’s top decision makers and is representative of the many countries in which we do business. Together, our leadership team is collectively focused on advancing Glenmark’s strategy and objectives. To learn more about our leadership team, click here.